Clinical Fellowships
Supports U.S. academic institutions in training physicians through multidisciplinary fellowships focused on the diagnosis, treatment, and research of ATTR Amyloidosis.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships)
Funding Amounts: Up to $95,000 per fellowship for one year; funds support fellow salary and benefits only.
Summary: Supports U.S. academic institutions in training physicians in ATTR Amyloidosis diagnosis, treatment, and research through multidisciplinary clinical fellowships.
Description
Alnylam Pharmaceuticals’ Clinical Fellowship Grants are designed to support educational clinical programs at U.S. academic institutions focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). These grants aim to advance the training of physicians in the diagnosis, treatment, and research of ATTR Amyloidosis, encouraging multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into patient care. Funding is provided exclusively for fellow salary and benefits and is intended for ACGME-accredited U.S. academic institutions with established Cardiology Fellowship Programs.
